{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Return to MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
  • Sign In
  • Home
  • Live
  • On-Demand
  • RSS/Grand Rounds
  • Non-Accredited
  • About
  • Contact Us
  • Help
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

MD Anderson workforce members:  Select "MD ANDERSON LOGIN" and enter your MD Anderson email address and password.

Guests (all other than MD Anderson workforce members): Select "GUEST LOGIN" and enter your email address and password.

MD ANDERSON LOGIN
GUEST LOGIN
Enter your email and password to login:

*
*
Login

New to CloudCME? Create an Account:

Create New Account
Back to Login Provider Forgot Your Password?

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
Email is required Invalid: Enter valid email address
First Name is required
Last Name is required
Password is required


Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =
Confirm password

Passwords must match
Password must be between 8 and 16 characters and contain the following:
•at least 1 upper case character
•at least 1 lower case character
•at least 1 numerical character
•at least 1 special character

  • -- Select Degree --
  • AA
  • AAS
  • ADN
  • BA
  • BS
  • BSN
  • DDS
  • DMD
  • DMin
  • DNP
  • DO
  • DrPH
  • DVM
  • DVM,PhD
  • EdD
  • JD
  • MA
  • MBA
  • MBBS
  • MBBS,MD
  • MD
  • MD, MBA
  • MD, MPH
  • MD, PhD
  • MDiv
  • MEd
  • MHA
  • MPA
  • MPH
  • MS
  • MSN
  • MSW
  • None
  • Other
  • PharmD
  • PharmD, PhD
  • PhD
  • PsyD
Degree is required
Please enter your degree:
You must enter a degree

Profession is required




Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.

please enter a term to search
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

2025 Hematopoietic Stem Cell and Myelodysplastic Syndromes (MDS) Symposium


LIVE
2025 Hematopoietic Stem Cell and Myelodysplastic Syndromes (MDS) Symposium Banner

  • Overview
  • Faculty
  • Schedule
  • Brochure
  • Hotel
  • Exhibitors
  • Register
Add to Calendar 2025 Hematopoietic Stem Cell and Myelodysplastic Syndromes (MDS) Symposium 5/21/2025 7:30:00 AM 5/22/2025 5:30:00 PM America/Chicago For More Details: https://mdanderson.cloud-cme.com/2025MDSSymp Description: Myelodysplastic Syndromes (MDS) continue to pose significant challenges in the field of hematologic oncology. Advancing treatment strategies for MDS hinges on a deeper understanding of the biological mechanisms governing hematopoietic stem cell function in both normal and stress conditions. To address this, the upcoming MDS symposium aims to bring together global experts specializing in various aspects of hematopoies... MD Anderson - Main Building, Hickey Auditorium (R11.1400) false MM/DD/YYYY


Date & Location
Wednesday, May 21, 2025, 7:30 AM - Thursday, May 22, 2025, 5:30 PM, MD Anderson - Main Building, Hickey Auditorium (R11.1400), Houston, TX

Target Audience
Specialties - Hematology, Hematopathology, Pathology
Professions - Other, Physician (MD or DO), Student or Trainee

Credits
AMA PRA Category 1 Credits™ (13.75 hours), Non-Physician Attendance (13.75 hours)

Overview
Myelodysplastic Syndromes (MDS) continue to pose significant challenges in the field of hematologic oncology. Advancing treatment strategies for MDS hinges on a deeper understanding of the biological mechanisms governing hematopoietic stem cell function in both normal and stress conditions. To address this, the upcoming MDS symposium aims to bring together global experts specializing in various aspects of hematopoiesis and MDS. This collaborative effort seeks to facilitate knowledge exchange, foster new insights, and drive forward molecular and therapeutic discoveries in the field of MDS. By convening leaders from around the world, the symposium aims to catalyze progress in understanding and treating this complex blood cancer.

Objectives
At the conclusion of this activity, learners will be able to:

  1. Analyze the biological mechanisms underlying hematopoietic stem cell maintenance in both physiological and stress conditions as they relate to MDS pathogenesis.
  2. Discuss current and emerging treatment strategies for MDS based on the latest understanding of hematopoietic stem cell biology.
  3. Interpret diagnostic findings and assess prognostic factors, including molecular analyses, for improved patient management.

Registration

On-site registration for the 2025 Hematopoietic Stem Cell and Myelodysplastic Syndromes (MDS) Symposium, will open at 7:00 AM on Wednesday, May 21, 2025. The symposium will begin with opening remarks at 8:30 AM and will adjourn for the day at 5:00 PM. The symposium will reconvene on Thursday, May 22, 2025 at 8:30 AM and adjourn at 4:30 PM. Advanced registration is encouraged as space and materials are limited. 

Please see registration form for applicable fees. If you are considering attending this symposium, please follow the link below to create a profile in PEP prior to registering: https://mdanderson.cloud-cme.com/default.aspx

The deadline for advanced registration is April 25, 2025.

Registration is now closed, you may register on-site.

Registration Fees:

CONFERENCE REGISTRATION FEES:

Non-MD Anderson Physicians

Postmarked before April 25, 2025

$150.00

Postmarked after April 25, 2025

$175.00

MD Anderson Physicians

Postmarked before April 25, 2025

$125.00

Postmarked after April 25, 2025

$145.00

Researchers/ Scientists/ Allied Healthcare Professionals

Postmarked before April 25, 2025

$75.00

Postmarked after April 25, 2025

$90.00

Students/ Trainees (Letter of Verification Required)

Postmarked before April 25, 2025

$35.00

Postmarked after April 25, 2025

$35.00

Telephone registrations are not accepted.

We accept the following forms of payment:
Credit Cards (MasterCard, VISA, and American Express)
Check (Payable to The University of Texas MD Anderson Cancer Center; through U.S. banks only)

Mail checks to:
   Continuing Professional Education (CPE) – Unit 1781
   The University of Texas MD Anderson Cancer Center
   P.O. Box 301407
   Houston, Texas 77230-1407

When registering online a receipt (confirmation letter) will be automatically emailed to the e-mail address you list on your profile during the process. 

Refund/Cancellation Policy
The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before April 25, 2025.  No refunds will be granted after this date.  The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check. 

The Department of Continuing Professional Education (CPE) reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or at the phone or fax numbers given on the registration form.  In case of activity cancellation, the liability of the CPE is limited to the registration fee. CPE will refund the full registration fee. 

CPE reserves the right to limit the number of participants in an activity and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available. 

Special Assistance or Additional Information
Contact Continuing Professional Education/Activity Management at 713-792-2223 or toll free at 866-849-5866 or via e-mail: [email protected].

Evaluation
A course evaluation tool will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status.  Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics. 


Accreditation

 

Accreditation
In support of improving patient care, The University of Texas MD Anderson Cancer Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Designation
The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Additional Information

View the accessibility policy for The University of Texas M.D Anderson Cancer Center.

 


Hotel Options: 

Houston Marriott Medical Center
6580 Fannin Street
Houston TX, 77030
713-796-0080
Room Rate:  Varies

Hilton Houston Plaza/Medical Center
6633 Travis Street
Houston TX  77030
713-313-4000
Room Rate:  Varies

DoubleTree by Hilton Houston Medical Center Hotel & Suites
6800 Main Street
Houston, TX  77030
713-528-7744
Rom Rate:  Varies

Hilton Garden Inn Houston Medical Center
6840 Almeda Rd.
Houston, Texas 77030
346-433-8200
Rom Rate:  Varies



The University of Texas MD Anderson Cancer Center complies with all requirements of the identified accrediting body  (ACCME, ANCC, ACPE). Disclosure of speakers, faculty members, planning committee members and their commercial relationships will be shared with learners prior to the educational activity.



Mitigation of Relevant Financial Relationships


The University of Texas MD Anderson Cancer Center adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Member Information
Role in activity
Nature of Relationship(s) / Name of Ineligible Company(s)
Amar Preet, MHA, MBA
MD Anderson Cancer Center
Activity Administrator
Nothing to disclose
Guillermo Garcia-Manero, MD
Professor, Leukemia
The University of Texas MD Anderson Cancer Center
Co-Director, Faculty
Nothing to disclose
Simona Colla, PhD
University of Texas MD Anderson Cancer Center
Course Director, Faculty
Nothing to disclose
Vera Adema Llobet, PhD
PhD
MD Anderson
Faculty
Nothing to disclose
Ioannis Aifantis, PhD
NYU Langone Health
Faculty
Nothing to disclose
Michael Andreeff, MD PhD
Professor
UT MD Anderson Cancer Center
Faculty
Grant or research support-Abbvie (Relationship has ended)|Grant or research support-AstraZeneca US (Relationship has ended)|Grant or research support-Daiichi Sankyo, Inc. (Relationship has ended)|Grant or research support-Aptose (Relationship has ended)|Grant or research support-Ascentage (Relationship has ended)|Grant or research support-Glycomimetics (Relationship has ended)|Grant or research support-Syndax|Grant or research support-Oxford (Relationship has ended)|Grant or research support-Kintor (Relationship has ended)|Grant or research support-Sellas|Grant or research support-ONA Therapeutics|Grant or research support-CPRIT|Grant or research support-NCI|Grant or research support-FDA|Grant or research support-MD Anderson MoonShot|Grant or research support-Break Through Cancer|Consulting Fee-Aptose (Relationship has ended)|Consulting Fee-Eterna|Consulting Fee-SentiBio|Consulting Fee-Glycomimetics (Relationship has ended)|Consulting Fee-Daiichi Sankyo, Inc. (Relationship has ended)|Consulting Fee-Ellipses|Consulting Fee-Moleculin|Consulting Fee-Paraza|Stocks or stock options, excluding diversified mutual funds-Reata (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Eterna|Stocks or stock options, excluding diversified mutual funds-SentiBio|Stocks or stock options, excluding diversified mutual funds-Eutropics|Stocks or stock options, excluding diversified mutual funds-Chimerix|Stocks or stock options, excluding diversified mutual funds-Oncolyze|Stocks or stock options, excluding diversified mutual funds-OncoBioTherapeutics (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Cancer UK
Luis Batista, PhD
Associate Professor
Washington University in St. Louis
Faculty
Nothing to disclose
Dominique Bonnet, PhD, Fellow of the Academy of Medical Sciences, UK
Principal Group Leader
The Francis Crick Institute
United Kingdom
Faculty
Nothing to disclose
Laura Calvi, MD
Professor of Medicine
Wilmot Cancer Institute
Faculty
Nothing to disclose
Fernando Camargo, PhD
Principal Investigator / Professor
Boston Children's Hospital
Faculty
Nothing to disclose
May Daher, MD
Assistant Professor, Stem Cell Transplantation
The University of Texas MD Anderson Cancer Center
Faculty
Royalties or Patent Beneficiary-Takeda
Matteo Giovanni Della Porta, MD, Professor of Hematology
Prof
Humanitas Research Hospital & Humanitas University, Milan Italy
Italy
Faculty
Nothing to disclose
Ronald DePinho, MD
Professor
MD Anderson Cancer Center
Faculty
Advisor-Aveo Oncology|Advisor-Bectas Therapeutics|Advisor-Asylia Therapeutics|Advisor-Tvardi Therapeutics|Advisor-Sporos Bioventures
John E Dick, PhD
University Health Network
Canada
Faculty
Grant or research support-Bristol-Myers Squibb Company (Relationship has ended)|Royalties or Patent Beneficiary-Pfizer Inc.|Membership on Advisory Committees or Review Panels, Board Membership, etc.-AstraZeneca US (Relationship has ended)
Margaret Goodell, PhD
Professor and Chair
Baylor College of Medicine
Faculty
Nothing to disclose
Stephanie Halene, MD
Professor
Yale University School of Medicine
Faculty
Grant or research support-AstraZeneca US|Grant or research support-STORM Therapeutics
Franco Izzo, PhD, Assistant Professor
Assistant Professor
Icahn School of Medicine at Mount Sinai
Faculty
Nothing to disclose
Siddhartha Jaiswal, MD, PhD
Stanford University
Faculty
Consulting Fee-AstraZeneca US (Relationship has ended)|Honoraria-Merck Research Laboratories and the Office of the Chief Medical Officer Grants (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Big Sur Bio
Katherine Y King, MD, PhD
Professor
Baylor College of Medicine
Faculty
Nothing to disclose
Stavroula CD Kousteni, PhD
Professor
Columbia University Medical Center
Faculty
Nothing to disclose
Sanam Loghavi, MD
Associate Professor
MD Anderson Cancer Center
Faculty
Advisor-AbbVie Inc.|Advisor-recordati (Relationship has ended)|Advisor-Cogent Biosciences (Relationship has ended)|Consulting Fee-AbbVie Inc.|Consulting Fee-Guidepoint, QualWorld, Gerson Lehman Group, Caris Diagnostics, Alphasight (Relationship has ended)|Advisor-Blueprint Medicines Corporation (Relationship has ended)|Advisor-Daiichi Sankyo, Inc. (Relationship has ended)|Consulting Fee-Daiichi Sankyo, Inc. (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-AbbVie Inc.|Grant or research support-Amgen Inc.|Grant or research support-Astellas Scientific and Medical Affairs, Inc.
Daniel Lucas, Ph.D.
Associate Professor
Cincinnati Children's Hospital Medical Center
Faculty
Nothing to disclose
Kellie Machlus, PhD
Boston Children's Hospital
Faculty
Nothing to disclose
Jaroslaw Maciejewski, MD, Ph. D
Chairman and Professor of Medicine
Cleveland Clinic
Faculty
Grant or research support-Novartis Pharmaceuticals Corporation|Advisor-Novartis Pharmaceuticals Corporation (Relationship has ended)|Grant or research support-Alexion Pharmaceuticals, Inc.|Advisor-Alexion Pharmaceuticals, Inc. (Relationship has ended)
Ravi Majeti, MD, PhD
Director, Institute for Stem Cell Biology and Regenerative Medicine
Stanford University
Faculty
Advisor-Kodikaz Therapeutic Solutions|Membership on Advisory Committees or Review Panels, Board Membership, etc.-858 Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Prelude Therapeutics|Advisor-Mubadala Capital|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Aculeus Therapeutics|Ownership-Orbital Therapeutics|Ownership-Pheast Therapeutics|Ownership-Myelogene
Michael D Milsom, PhD
Division Head
German Cancer Research Center (DKFZ)
Germany
Faculty
Nothing to disclose
Guillermo Montalban-Bravo, MD
University of Texas MD Anderson Cancer Center
Faculty
Grant or research support-IFM Therapeutics|Grant or research support-Takeda Oncology|Grant or research support-Solu Therapeutics
Sean Morrison, PhD, Investigator, HHMI
UT Southwestern Dallas
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-Garuda Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kojin Therapeutics|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Inception Therapeutics|Advisor-Conception Biosciences
Eirini Papapetrou, PhD
Icahn School of Medicine at Mount Sinai
Faculty
Consulting Fee-Celgene Corporation
Emmanuelle Passegué, PhD
Director
Columbia University Irving Medical Center
Faculty
Nothing to disclose
Eric Pietras, PhD
University of Colorado Anschutz Medical Campus
Faculty
Nothing to disclose
Valeria Santini, MD
MD, Prof
AOU Careggi University of Florence
Italy
Faculty
Membership on Advisory Committees or Review Panels, Board Membership, etc.-AbbVie Inc. (Relationship has ended)|Honoraria-Jazz Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Servier Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-GlaxoSmithKline|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol-Myers Squibb Company|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Pharmaceuticals Corporation|Honoraria-Novartis Pharmaceuticals Corporation|Advisor-Otsuka America, Inc. (Relationship has ended)
Ulrich Steidl, MD, PhD
Faculty
Grant or research support-GlaxoSmithKline|Grant or research support-Bayer HealthCare Pharmaceuticals, Inc.|Grant or research support-Aileron Therapeutics|Grant or research support-Novartis Pharmaceuticals Corporation|Consulting Fee-Roche|Consulting Fee-Novartis Pharmaceuticals Corporation|Consulting Fee-Bayer HealthCare Pharmaceuticals, Inc.|Consulting Fee-Aileron Therapeutics|Consulting Fee-Stelexis Therapeutics|Consulting Fee-Pieris Pharmaceuticals|Ownership-Stelexis Therapeutics|Ownership-Roshon Therapeutics
Koichi Takahashi, MD PhD
Associate Professor - Leukemia
The University of Texas MD Anderson Cancer Center
Faculty
Consulting Fee-Novartis Pharmaceuticals Corporation|Honoraria-Amgen Inc. (Relationship has ended)|Consulting Fee-Agios Pharmaceuticals Inc.|Consulting Fee-Meiji Pharma|Consulting Fee-Symbio Pharmaceuticals|Consulting Fee-GlaxoSmithKline|Consulting Fee-Bristol-Myers Squibb Company|Consulting Fee-Celgene Corporation|Honoraria-Mission Bio|Honoraria-Otsuka Pharmaceuticals |Honoraria-Illumina
Natthakan Thongon, PhD
Ph.D
MD Anderson Cancer Center
Faculty
Nothing to disclose
Andreas Trumpp, PhD
Prof. Dr.
HI-STEM gGmbH and German Cancer Research Center (DKFZ)
Germany
Faculty
Nothing to disclose
David Valcárcel Ferreiras, MD, PhD
Dr
Vall d'Hebron University Hospital
Spain
Faculty
Consulting Fee-AbbVie Inc.|Other: Meeting, travel, accomodation-AbbVie Inc.|Honoraria-Agios Pharmaceuticals Inc.|Other: Meeting, travel, accomodation-Agios Pharmaceuticals Inc.|Consulting Fee-Amgen Inc.|Honoraria-Amgen Inc.|Advisor-Amgen Inc.|Other: Meeting, travel, accomodation-Amgen Inc.|Consulting Fee-Astellas Scientific and Medical Affairs, Inc.|Honoraria-Astellas Scientific and Medical Affairs, Inc.|Consulting Fee-Bristol-Myers Squibb Company|Honoraria-Bristol-Myers Squibb Company|Advisor-Bristol-Myers Squibb Company|Grant or research support-Bristol-Myers Squibb Company|Other: Meeting, travel, accomodation-Bristol-Myers Squibb Company|Honoraria-Gebro|Honoraria-Grifols|Advisor-Grifols|Other: Meeting, travel, accomodation-Grifols|Honoraria-Janssen Biotech, Inc.|Consulting Fee-Jazz Pharmaceuticals|Honoraria-Jazz Pharmaceuticals|Advisor-Jazz Pharmaceuticals|Other: Meeting, travel, accomodation-Jazz Pharmaceuticals|Consulting Fee-Gilead Sciences, Inc.|Honoraria-Gilead Sciences, Inc.|Consulting Fee-Merck Sharp & Dohme Corp. (any division)|Honoraria-Merck Sharp & Dohme Corp. (any division)|Consulting Fee-Novartis Pharmaceuticals Corporation|Honoraria-Novartis Pharmaceuticals Corporation|Advisor-Novartis Pharmaceuticals Corporation|Other: Meeting, travel, accomodation-Novartis Pharmaceuticals Corporation|Honoraria-Pfizer Inc.|Consulting Fee-Sanofi US|Honoraria-Sanofi US|Other: Meeting, travel, accomodation-Sanofi US|Advisor-Servier Pharmaceuticals|Consulting Fee-Sobi|Honoraria-Sobi|Advisor-Sobi|Other: Meeting, travel, accomodation-Sobi|Consulting Fee-Takeda|Honoraria-Takeda
Amit Verma, MD
Albert Einstein College of Medicine
Faculty
Grant or research support-Bristol-Myers Squibb Company
Britta Will, PhD
Albert Einstein College of Medicine
Faculty
Nothing to disclose
Leonard Zon, MD
Boston Children's Hospital
Faculty
Nothing to disclose
Lisa Palacios, MBA
Program Manager
MD Anderson Cancer Center
Other Planning Committee Member
Nothing to disclose

Wednesday, May 21, 2025
Welcome Introduction
8:30AM - 8:40AM
Simona Colla, PhD
Session 1 Introduction: New advances in understanding the hematopoietic system
8:40AM - 8:45AM
Simona Colla, PhD
Keynote: What makes a stem cell a stem cell and how does it go bad?
8:45AM - 9:30AM
John E Dick, PhD

Hematopoietic Stem Cells in Stress, Disease and Aging
9:30AM - 9:45AM
Emmanuelle Passegué, PhD

The Stem Cell Niche and Implications for Clinical Transplantation
9:45AM - 10:00AM
Sean Morrison, PhD, Investigator, HHMI
Response and Resistance of Leukemic Stem Cells to Venetoclax
10:00AM - 10:15AM
Andreas Trumpp, PhD
Discussion - New Advances in Understanding the Hematopoietic System
10:15AM - 10:30AM
Break and Exhibits
10:30AM - 10:45AM
Session 2 Introduction: Hematopoiesis Under Other Stress
10:45AM - 10:50AM
Simona Colla, PhD
Keynote - Telomeres and Telomerase in Cancer and Aging
10:50AM - 11:35AM
Ronald DePinho, MD
Pre-Malignant Programming of HSCs During Aging
11:35AM - 11:50AM
Michael D Milsom, PhD
Chaperone-mediated Autophagy Drives Resistance to Azacytidine and Venetoclax in Leukemic Stem Cells
11:50AM - 12:05PM
Britta Will, PhD
Maladaptive Somatic Mutations in Telomere Biology Disorders
12:05PM - 12:20PM
Simona Colla, PhD
Post-transcriptional Regulation of ncRNA Stability: A Central Modulator of Hematopoietic Development and Disease
12:20PM - 12:35PM
Luis Batista, PhD
Discussion - Hematopoiesis Under Other Stress
12:35PM - 12:50PM
Lunch and Exhibits
12:50PM - 1:50PM
Session 3 Introduction: Hematopoiesis and Inflammation
1:50PM - 1:55PM
Vera Adema Llobet, PhD
Microbiota Regulation of Hematopoiesis
1:55PM - 2:10PM
Katherine Y King, MD, PhD
Intersections Between Inflammation and Metabolism in Myeloid Pathogenesis
2:10PM - 2:25PM
Eric Pietras, PhD

Inflammation and MDS
2:25PM - 2:40PM
Amit Verma, MD
How do TET2 Mutations Confer Clonal Fitness?
2:40PM - 2:55PM
Eirini Papapetrou, PhD
Discussion - Hematopoiesis and Inflammation
2:55PM - 3:10PM
Break and Exhibits
3:10PM - 3:20PM
Session 4 Introduction: Microenvironment (Part 1)
3:20PM - 3:35PM
Michael Andreeff, MD PhD

Keynote - Stem Cell Clonality and the Niche
3:35PM - 4:20PM
Leonard Zon, MD
Microenvironmental Drivers of MDS Pathogenesis and Treatment
4:20PM - 4:35PM
Stavroula CD Kousteni, PhD
From CH to MDS: Role of the Microenvironment in the Expansion of the Malignant Clone(s)
4:35PM - 4:50PM
Dominique Bonnet, PhD, Fellow of the Academy of Medical Sciences, UK
The Role of Microenvironment in MDS Progression
4:50PM - 5:05PM
Laura Calvi, MD
Discussion - Microenvironment (Part 1)
5:05PM - 5:10PM
Adjourn
5:10PM - 5:11PM
Thursday, May 22, 2025
Welcome
9:00AM - 9:05AM
Simona Colla, PhD
Session 1 Introduction: Clonal Hematopoiesis and MDS
9:05AM - 9:10AM
Guillermo Montalban-Bravo, MD

Understanding and Targeting Progression in RUNX1 FPD - No CMEs awarded
9:10AM - 9:25AM
Ulrich Steidl, MD, PhD

Break and Exhibits
9:25AM - 9:55AM

DNMT3A in Normal and Malignant Hematopoiesis
9:55AM - 10:10AM
Margaret Goodell, PhD

Exploiting METTL3 Inhibition in MDS
10:10AM - 10:25AM
Stephanie Halene, MD

Immunologic Somatic Gene Rescue via Immune Target Mutations as Marker of Tumor Surveillance
10:25AM - 10:40AM
Jaroslaw Maciejewski, MD, Ph. D

Systematic Investigation of Factors Mediating Clonal Expansion in CHIP
10:40AM - 10:55AM
Siddhartha Jaiswal, MD, PhD

Tet2 Age-associated Somatic Mutations Impair Megakaryopoiesis in Clonal Hematopoiesis
10:55AM - 11:10AM
Kellie Machlus, PhD

Discussion - Clonal Hematopoiesis and MDS
11:10AM - 11:25AM

Session 2 Introduction: Microenvironment (Part II) and Immune System in MDS
11:25AM - 11:30AM
Natthakan Thongon, PhD

Anatomical Regulation of Hematopoiesis
11:30AM - 11:45AM
Daniel Lucas, Ph.D.

Immune Dysfunction in the MDS Microenvironment
11:45AM - 12:00PM
Ioannis Aifantis, PhD

Epigenetic Scarring in Myeloid Malignancies
12:00PM - 12:15PM
May Daher, MD

Discussion - Microenvironment (Part II) and Immune System in MDS
12:15PM - 12:30PM

Lunch and Exhibits
12:30PM - 1:00PM

Session 3 Introduction: Innovative Technologies
1:00PM - 1:05PM
Koichi Takahashi, MD PhD
Keynote - Ancestry and Function in the Hematopoietic System
1:05PM - 1:50PM
Fernando Camargo, PhD
Stem Cells in Human Myeloid Malignancies
1:50PM - 2:05PM
Ravi Majeti, MD, PhD
Insights into Leukemia Evolution from iPSC Models
2:05PM - 2:20PM

Genotype to Phenotgype Mapping in Single Cells: Uncovering Mutation-Driven Malignant Phenotypes in Blood Malignancies
2:20PM - 2:35PM
Franco Izzo, PhD, Assistant Professor

Discussion: Innovative Technologies
2:35PM - 2:50PM

Break and Exhibits
2:50PM - 3:05PM

Session 4 Introduction: MDS New Therapies
3:05PM - 3:20PM

Novel Insights into the Pathogenesis of Therapy-related MDS
3:20PM - 3:35PM
Koichi Takahashi, MD PhD

Update on Harmonization of MDS Classification: Where Are We Now and Could an 'Immune Score' be the Uniter?
3:35PM - 3:50PM
Sanam Loghavi, MD

Methylation and Aging in Lower Risk MDS
3:50PM - 4:05PM
Valeria Santini, MD

AI to Improve Personalized Medicine in MDS
4:05PM - 4:20PM
Matteo Giovanni Della Porta, MD, Professor of Hematology

When and How to Transplant a Patient with MDS
4:20PM - 4:35PM
David Valcárcel Ferreiras, MD, PhD

New Therapies for HMA Failure
4:35PM - 4:50PM
Guillermo Garcia-Manero, MD

Thank you for your interest in the 2025 Hematopoietic Stem Cell and Myelodysplastic Syndromes (MDS) Symposium. Due to an overwhelming response, we have reached full capacity and are no longer accepting registrations.

We appreciate your support and hope that you can participate in other upcoming activities.

Thank you for your understanding.
________________________________________________________________________________________________________________________________________


Contact Us:
Cicely A. Simon, Manager, Continuing Education
Continuing Professional Education – Unit 1781
The University of Texas MD Anderson Cancer Center
PO Box 301407
Houston, TX 77230-1407
Phone: 281-813-4261
Email: [email protected]


W9 Form

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
 Privacy policies   

©2023 The University of Texas MD Anderson Cancer Center
Contact Us: [email protected]

See us on Facebook See us on Twitter See us on Linked In See us on Instagram